{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:01:46Z","timestamp":1761562906325,"version":"3.37.3"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical sciences","doi-asserted-by":"publisher","award":["99-01-01-22832"],"award-info":[{"award-number":["99-01-01-22832"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Object(s):<\/jats:title>\n<jats:p>Shortly after cancer is diagnosed, a phenomenon develops in cancer\ncells called multidrug resistance (MDR), in which cell sensitivity against anti-cancer drugs\nis significantly reduced. The present investigation aimed to assess the effects of nitazoxanide\n(NTZ), a safe drug, on LS174T\/OXP-resistant cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In the current in vitro research, the effects of NTZ and oxaliplatin (OXP) on the\nviability of LS174T and LS174T\/OXP cell lines were evaluated through MTT assay. Then,\nthe changes in expression levels of MDR1, MRP1, BCRP, and LRP genes and proteins\nwere measured by RT-qPCR and western blotting methods, respectively. Lastly, the\napoptosis status was assessed by annexin V\u2013FITC\/PI staining flow cytometry assay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The IC50 values for cells resistant or sensitive to OXP were revealed (11567 nM\nvs. 1745 nM; p &lt;0.05 for 24 h incubation, and 5161 nM vs. 882.2 nM; p &lt;0.05 for 48 h\nincubation). Moreover, NTZ plus OXP led to a leftward shift in the cytotoxicity curve (2004\nnM; p = 0.007). This co-treatment significantly decreased the expression of all genes and\nproteins (p &lt;0.05). Finally, the combination of NTZ and OXP induced a significant increase\nin apoptosis (p &lt;0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The data showed that NTZ treatment could increase the sensitivity of\nLS174T\/OXP cell line to the OXP cytotoxic effects. Thus, NTZ may be efficient in reducing\ndrug resistance in clinics by means of the negative regulation of ATP-binding cassette\n(ABC) transporters. However, further studies are necessary to explain the exact mechanisms\nof NTZ.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524023666220820154623","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T04:38:00Z","timestamp":1661229480000},"page":"834-841","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin\nand Nitazoxanide: Targeting the ABC Transporters"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-370X","authenticated-orcid":true,"given":"Mohsen","family":"Hemmati-Dinarvand","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Kashan University of Medical Sciences, Kashan,\nIran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-0788","authenticated-orcid":true,"given":"Hossein","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences,\nSari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Alipourfard","sequence":"additional","affiliation":[{"name":"Institutitue of Biology, Biotechnology and Environmental Protection, Faculty of Natural Sciences,\nUniversity of Silesia, Katowice, Poland"},{"name":"Bonn-Rhein-Sieg University of Applied Sciences, Department of Natural\nSciences &amp;amp, Institute for Functional Gene Analytics (IFGA), Rheinbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Beyrami Aghbash","sequence":"additional","affiliation":[{"name":"Department of\nMedical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-6766","authenticated-orcid":true,"given":"Shahnaz","family":"Kheirandish","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khodadadian","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefeh","family":"Seghatoleslam","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"103122","DOI":"10.1016\/j.critrevonc.2020.103122","volume":"157","author":"Zieli\u0144ska A.","year":"2021","unstructured":"Zieli\u0144ska A.; W\u0142odarczyk M.; Makaro A.; Sa\u0142aga M.; Fichna J.; Management of pain in colorectal cancer patients. Crit Rev Oncol Hematol 2021,157,103122","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcdb.2016.08.033","volume":"64","author":"Zhai Z.","year":"2017","unstructured":"Zhai Z.; Yu X.; Yang B.; Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol 2017,64,107-115","journal-title":"Semin Cell Dev Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2174\/0929867325666180105103637","volume":"26","author":"Ceballos M.P.","year":"2019","unstructured":"Ceballos M.P.; Rigalli J.P.; Cer\u00e9 L.I.; Semeniuk M.; Catania V.A.; Ruiz M.L.; ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem 2019,26(7),1224-1250","journal-title":"Curr Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2020.02.007","volume":"476","author":"Gao Q.","year":"2020","unstructured":"Gao Q.; Li X.X.; Xu Y.M.; IRE1\u03b1-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett 2020,476,67-74","journal-title":"Cancer Lett"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1002\/jcp.26406","volume":"233","author":"Hsu H.H.","year":"2018","unstructured":"Hsu H.H.; Chen M.C.; Baskaran R.; Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol 2018,233(7),5458-5467","journal-title":"J Cell Physiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.biopha.2018.08.041","volume":"107","author":"Lin H.","year":"2018","unstructured":"Lin H.; Yang G.; Yu J.; KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1. Biomed Pharmacother 2018,107,1205-1209","journal-title":"Biomed Pharmacother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2018.10.020","volume":"442","author":"De Vera A.A.","year":"2019","unstructured":"De Vera A.A.; Gupta P.; Lei Z.; Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1) mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Lett 2019,442,91-103","journal-title":"Cancer Lett"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"648407","DOI":"10.3389\/fphar.2021.648407","volume":"12","author":"Xiao H.","year":"2021","unstructured":"Xiao H.; Zheng Y.; Ma L.; Tian L.; Sun Q.; Clinically relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol 2021,12,648407","journal-title":"Front Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/jnci\/91.19.1647","volume":"91","author":"Kitazono M.","year":"1999","unstructured":"Kitazono M.; Sumizawa T.; Takebayashi Y.; Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999,91(19),1647-1653","journal-title":"J Natl Cancer Inst"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/cancers11101576","volume":"11","author":"Hsu H.H.","year":"2019","unstructured":"Hsu H.H.; Kuo W.W.; Shih H.N.; FOXC1 regulation of miR-31-5p confers oxaliplatin resistance by targeting LATS2 in colorectal cancer. Cancers 2019,11(10),1576","journal-title":"Cancers"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.biopha.2018.04.105","volume":"103","author":"Pirpour Tazehkand A.","year":"2018","unstructured":"Pirpour Tazehkand A.; Akbarzadeh M.; Velaie K.; Sadeghi M.R.; Samadi N.; The role of Her2-NRF2 axis in induction of oxaliplatin resistance in colon cancer cells. Biomed Pharmacother 2018,103,755-766","journal-title":"Biomed Pharmacother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"Rossignol J.F.","year":"2014","unstructured":"Rossignol J.F.; Nitazoxanide: A first in class broad spectrum antiviral agent. Antiviral Res 2014,110,94-103","journal-title":"Antiviral Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41417-020-00239-8","volume":"28","author":"Yu J.","year":"2021","unstructured":"Yu J.; Yang K.; Zheng J.; Zhao W.; Sun X.; Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. Cancer Gene Ther 2021,28(6),590-601","journal-title":"Cancer Gene Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1139\/cjpp-2020-0449","volume":"99","author":"Behrouj H.","year":"2021","unstructured":"Behrouj H.; Seghatoleslam A.; Mokarram P.; Ghavami S.; Effect of casein kinase 1\u03b1 inhibition on autophagy flux and the AKT\/phospho-\u03b2-catenin (S552) axis in HCT116, a RAS-mutated colorectal cancer cell line. Can J Physiol Pharmacol 2021,99(3),284-293","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"prot5439","DOI":"10.1101\/pdb.prot5439","volume":"2010","author":"Rio D.C.","year":"2010","unstructured":"Rio D.C.; Ares M.; Hannon G.J.; Nilsen T.W.; Purification of RNA using trizol (TRI reagent). Cold Spring Harb Protoc 2010,2010(6),prot5439","journal-title":"Cold Spring Harb Protoc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-62703-002-1_6","volume":"926","author":"Hirano S.","year":"2012","unstructured":"Hirano S.; Western blot analysis. Methods Mol Biol 2012,926,87-97","journal-title":"Methods Mol Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/cbdd.13078","volume":"91","author":"Shafiei-Irannejad V.","year":"2018","unstructured":"Shafiei-Irannejad V.; Samadi N.; Yousefi B.; Salehi R.; Velaei K.; Zarghami N.; Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp-overexpressing MCF-7 cells. Chem Biol Drug Des 2018,91(1),269-276","journal-title":"Chem Biol Drug Des"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"111860","DOI":"10.1016\/j.yexcr.2020.111860","volume":"388","author":"Madigan J.P.","year":"2020","unstructured":"Madigan J.P.; Robey R.W.; Poprawski J.E.; A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. Exp Cell Res 2020,388(2),111860","journal-title":"Exp Cell Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.arcmed.2021.12.001","volume":"53","author":"Hemmati-Dinarvand M.","year":"2021","unstructured":"Hemmati-Dinarvand M.; Ahmadvand H.; Seghatoleslam A.; Nitazoxanide and cancer drug resistance: Targeting Wnt\/\u03b2-catenin signaling pathway. Arch Med Res 2021,53(3),263-270","journal-title":"Arch Med Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.biopha.2014.10.019","volume":"68","author":"Kozovska Z.","year":"2014","unstructured":"Kozovska Z.; Gabrisova V.; Kucerova L.; Colon cancer: Cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother 2014,68(8),911-916","journal-title":"Biomed Pharmacother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/cas.12223","volume":"104","author":"Shen D.Y.","year":"2013","unstructured":"Shen D.Y.; Zhang W.; Zeng X.; Liu C.Q.; Inhibition of Wnt\/\u03b2-catenin signaling downregulates P-glycoprotein and reverses multi drug resistance of cholangiocarcinoma. Cancer Sci 2013,104(10),1303-1308","journal-title":"Cancer Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/ijc.23755","volume":"123","author":"M\u00fcller J.","year":"2008","unstructured":"M\u00fcller J.; Sidler D.; Nachbur U.; Wastling J.; Brunner T.; Hemphill A.; Thiazolides inhibit growth and induce glutathione S transferase Pi (GSTP1) dependent cell death in human colon cancer cells. Int J Cancer 2008,123(8),1797-1806","journal-title":"Int J Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41419-018-1058-z","volume":"9","author":"Wang X.","year":"2018","unstructured":"Wang X.; Shen C.; Liu Z.; Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma. Cell Death Dis 2018,9(10),1032","journal-title":"Cell Death Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/s41388-019-1142-6","volume":"39","author":"Ripani P.","year":"2020","unstructured":"Ripani P.; Delp J.; Bode K.; Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain. Oncogene 2020,39(11),2345-2357","journal-title":"Oncogene"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.intimp.2012.03.002","volume":"13","author":"Hong S.K.","year":"2012","unstructured":"Hong S.K.; Kim H.J.; Song C.S.; Choi I.S.; Lee J.B.; Park S.Y.; Nitazoxanide suppresses IL-6 production in LPS stimulated mouse macrophages and TG injected mice. Int Immunopharmacol 2012,13(1),23-27","journal-title":"Int Immunopharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1535-7163.MCT-12-1243","volume":"12","author":"Fan M.H.","year":"2013","unstructured":"Fan M.H.; Bodapati S.; Solow C.D.; A c-Myc activation sensor based high throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther 2013,12(9),1896-1905","journal-title":"Mol Cancer Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nchembio.2510","volume":"14","author":"Qu Y.","year":"2018","unstructured":"Qu Y.; Olsen J.R.; Yuan X.; Small molecule promotes \u03b2-catenin citrullination and inhibits Wnt signaling in cancer. Nat Chem Biol 2018,14(1),94-101","journal-title":"Nat Chem Biol"},{"key":"ref=28","first-page":"2041","volume":"30","author":"Chikazawa N.","year":"2010","unstructured":"Chikazawa N.; Tanaka H.; Tasaka T.; Inhibition of Wnt signaling pathway decreases chemotherapy resistant side population colon cancer cells. Anticancer Res 2010,30(6),2041-2048","journal-title":"Anticancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1073\/pnas.1308362110","volume":"110","author":"Stadler S.C.","year":"2013","unstructured":"Stadler S.C.; Vincent C.T.; Fedorov V.D.; Dysregulation of PAD4-mediated citrullination of nuclear GSK3\u03b2 activates TGF-\u03b2 signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci USA 2013,110(29),11851-11856","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1093\/nar\/gku522","volume":"42","author":"Deplus R.","year":"2014","unstructured":"Deplus R.; Denis H.; Putmans P.; Citrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylation. Nucleic Acids Res 2014,42(13),8285-8296","journal-title":"Nucleic Acids Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s13046-019-1404-8","volume":"38","author":"Li F.","year":"2019","unstructured":"Li F.; Miao L.; Xue T.; Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen resistant breast cancer cells. J Exp Clin Cancer Res 2019,38(1),414","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2017.08.019","volume":"409","author":"Qin H.","year":"2017","unstructured":"Qin H.; Liu X.; Li F.; PAD1 promotes epithelial mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1\/2-MMP2 signaling. Cancer Lett 2017,409,30-41","journal-title":"Cancer Lett"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666220820154623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207812\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666220820154623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T10:25:22Z","timestamp":1695378322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207812\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524023666220820154623","relation":{},"ISSN":["1566-5240"],"issn-type":[{"type":"print","value":"1566-5240"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}